Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Urea + crosslinked-hyaluronate is a combination product consisting of the small molecule urea and a form of hyaluronic acid (hyaluronate) that has been chemically cross-linked using urea as the crosslinking agent. This formulation leverages the synergistic effects of both components for enhanced therapeutic benefit. Urea acts as a keratolytic and humectant, promoting hydration and softening of tissues, while crosslinked hyaluronate provides viscoelasticity, tissue adhesion, and prolonged residence time at application sites due to its gel-like structure. The combination has demonstrated anti-inflammatory properties, improved wound healing capacity, and potential antioxidant effects in preclinical studies. It is being explored primarily for topical or local administration in conditions involving inflammation or tissue damage—such as skin diseases (cutaneous disorders), rectal mucosal lesions[1], and inflammatory lung diseases[2][5]. Crosslinking with urea modifies the physical properties of hyaluronan gels to enhance their stability and biological activity[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on urea + crosslinked-hyaluronate.